НИСИМУРА Стивен (US),ЛОУ Цзяньлон (US),БАРОН Джоди Линн (US),МАРКС Джеймс Д. (US)
申请号：
RU2012139829/10
公开号：
RU2012139829A
申请日:
2011.02.18
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. An isolated antibody that specifically binds to ανβ8, where the antibody inhibits the release of the active, mature TGFβ peptide, but practically does not inhibit the adhesion of latent TGFβ to ανβ8 on an ανβ8-expressing cell. The isolated antibody of claim 1, wherein said antibody specifically binds to β8.3. The isolated antibody of claim 1, wherein said antibody specifically binds to an β8 epitope that is located within the polypeptide sequence of SEQ ID NO: 11.4. The isolated antibody of claim 1, wherein said antibody competes for binding to ανβ8 with an antibody having a light chain variable region comprising three light chain CDRs with SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and the variable region of the heavy chain containing three heavy chain CDRs with SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10.5. The isolated antibody of claim 1, wherein the antibody has a light chain variable region comprising three light chain CDRs with SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and a heavy chain variable region containing three heavy chain CDRs with SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10.6. The isolated antibody of claim 1, wherein the antibody has a light chain variable region with the sequence of SEQ ID NO: 3 or 4 and a heavy chain variable region with the sequence of SEQ ID NO: 1 or 2.7. The isolated antibody of claim 1, wherein the antibody is an IgG1, IgG2, IgG3, or IgG4.8 isotype. An isolated antibody according to claim 1, wherein the antibody is a monoclonal antibody. The isolated antibody of claim 1, wherein the antibody is a human, humanized, or chimeric antibody. A pharmaceutical composition comprising an antibody according to claim 1. and a pharmaceutically acceptable excipient. 11. Isolated nucleic acid encoding1. Изолированное антитело, которое специфически связывается с ανβ8, где антитело ингибирует высвобождение активного, зрелого пептида TGFβ, но практически не ингибируют адгезию латентного TGFβ к ανβ8 на ανβ8-экспрессирующей клетке.2. Изолированное
